NCT03952390

Brief Summary

As a common and serious medical condition , sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection , which is a major and familiar cause of death in intensive care units(ICU). As a frequent laboratory abnormality in patients with sepsis , thrombocytopenia on intensive care unit admission is independently associated with increased mortality in patients. Furthermore, a low platelet count is a marker with further significance , which is always used for evaluating the prognosis of patients. Herein, this study aimed to investigate the effect of renin-angiotensin system on thrombocytopenia in patient with sepsis and explore the possible underlying molecular mechanisms.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
53

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2018

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

January 15, 2019

Completed
4 months until next milestone

First Posted

Study publicly available on registry

May 16, 2019

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 10, 2019

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2019

Completed
Last Updated

January 18, 2020

Status Verified

December 1, 2018

Enrollment Period

1.9 years

First QC Date

January 15, 2019

Last Update Submit

January 14, 2020

Conditions

Keywords

thrombocytopenia,Renin-Angiotensin System,platelet

Outcome Measures

Primary Outcomes (3)

  • Platelet Count of Blood Sample

    The platelet count of venous blood samples collected from patients with sepsis was measured by Blood routine instrument,Beckman CoulterLH750.

    20-60min

  • The Plasma Renin Activity of Blood Sample

    Venous blood samples were collected in ethylenediaminetetraacetic acid (EDTA),dimercaptopropanol and 8 - hydroxyquinoline sulfate plus blood collection tubes, followed by centrifugation to separate plasma from venous blood samples.The plasma renin activity of venous blood samples collected from patients with sepsis was measured by Iodine\[125I\]AngiotensinⅡRadioimmunoassay Kit.

    20-60min

  • The Plasma Concentration of AngiotensinⅡ in Blood Sample

    Venous blood samples were collected in ethylenediaminetetraacetic acid (EDTA) ,dimercaptopropanol and 8 - hydroxyquinoline sulfate plus blood collection tubes, followed by centrifugation to separate plasma from venous blood samples.The plasma concentration of angiotensinⅡ in venous blood samples collected from patients with sepsis was measured by Iodine\[125I\]AngiotensinⅡRadioimmunoassay Kit.

    20-60min

Secondary Outcomes (2)

  • Correlation Coefficient (r) Between Platelet Count and The Plasma Renin Activity

    20-60min

  • Correlation Coefficient (r) Between Platelet Count and The Plasma Concentration of AngiotensinⅡ

    20-60min

Study Arms (2)

control

healthy volunteers

Other: control

sepsis

patients with sepsis

Other: sepsis

Interventions

controlOTHER
Also known as: healthy volunteers
control
sepsisOTHER
Also known as: patients with sepsis
sepsis

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with sepsis

You may qualify if:

  • Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.
  • Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection.
  • The baseline SOFA score can be assumed to be zero in patients not known to have preexisting organ dysfunction.
  • ASOFA score ≥2 reflects an overall mortality risk of approximately 10% in a general hospital population with suspected infection. Even patients presenting with modest dysfunction can deteriorate further,emphasizing the seriousness of this condition and the need for prompt and appropriate intervention, if not already being instituted.
  • In lay terms, sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs.
  • Patients with suspected infection who are likely to have a prolonged ICU stay or to die in the hospital can be promptly identified at the bedside with qSOFA, ie, alteration in mental status, systolic blood pressure ≥100 mm Hg, or respiratory rate ≥22/min.
  • Septic shock is a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality.
  • Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level \>2 mmol/L (18mg/dL) despite adequate volume resuscitation. With these criteria,hospital mortality is in excess of 40%.
  • Abbreviations: MAP, mean arterial pressure; qSOFA, quick SOFA; SOFA: Sequential\[Sepsis-related\] Organ Failure Assessment.

You may not qualify if:

  • Pregnant or lactation period.
  • Age \<18 years or \>85 years.
  • Receiving chemotherapy, steroid or immunosuppressive agents recently.
  • Receiving any drugs that affect Renin-Angiotensin-System(RAS),sunch as Angiotensin Converting Enzyme Inhibitor(ACEI),Angiotensin Receptor Blockers(ARB),diuretics,calcium channel blockers and other antihypertensives within two weeks .
  • Receiving oral contraceptives within twelve weeks.
  • Enrollment before resuscitation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Anesthesia, Shanghai Xinhua hospital

Shanghai, Shanghai Municipality, 200082, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

plasma seperated from venous blood via centrifugation

MeSH Terms

Conditions

SepsisThrombocytopenia

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsBlood Platelet DisordersHematologic DiseasesHemic and Lymphatic DiseasesCytopenia

Study Officials

  • Lai Jiang, chief doctor

    Xinhua Hospital affiliated to Medicine school,Shanghai Jiaotong University

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 15, 2019

First Posted

May 16, 2019

Study Start

January 1, 2018

Primary Completion

December 10, 2019

Study Completion

December 15, 2019

Last Updated

January 18, 2020

Record last verified: 2018-12

Locations